This article reports on a 78-year-old male patient with advanced pulmonary sarcomatoid car-cinoma with positive PD-L1 expression,who achieved partial remission(PR)and progression-free survival(PFS)of 30 months with sindilizumab and amilorotinib.Grade 2 hypertension and other transient cardiac problems occurred during treatment,but overall quality of life was good.
维普
万方数据